RayKnowChina Research Map
Shortlist0

RecruitingIdiopathic pulmonary fibrosisPhase 3

Registered title, quoted from ClinicalTrials.gov

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

An open trial on idiopathic pulmonary fibrosis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteChina-Japan Friendship Hospital中日友好医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07082842, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 40 years to 80 years; sex: all

    Registered eligibility fields

  2. Be diagnosed with IPF according to the diagnostic criteria of the IPF clinical practice guidelines jointly released by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society and the Latin American Thoracic Society in 2022 ; Chest high-resolution computed tomography (HRCT) examination (HRCT examination within 3 months before screening) or lung biopsy (if any) should be confirmed by central reading;

    Inclusion criterion 3

  3. Female or male subjects with potential fertility agree and commit to taking effective contraceptive measures from the time of signing the informed consent form until 30 days after the last administration of the investigational drug; at the same time, avoid sperm/egg collection, sperm/egg donation;

    Inclusion criterion 7

  4. The percentage of DLco (hemoglobin [Hb] corrected) as a percentage of the normal predicted value at the screening period is ≥ 30%;

    Inclusion criterion 6

    During the screening period, liver function test values exceeded any of the following standards: total bilirubin > 1.5 times the upper limit of normal (ULN); aspartate aminotransferase or alanine aminotransferase > 2 times ULN;

    Exclusion criterion 23

    During the screening period, glomerular filtration rate < 45 mL/min/1.73 m2, calculated using the CKD-EPI (based on serum creatinine) formula ;

    Exclusion criterion 24

  5. History of malignant tumors within the previous 5 years (excluding localized cancers such as basal cell carcinoma).

    Exclusion criterion 7

  6. Pregnant or breastfeeding;

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07082842, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily participate in this clinical study and sign the informed consent form before the study begins;
  • When signing the informed consent form, the age should be between 40 and 80 years old (inclusive of 40 and 80), and gender is not restricted;
  • Be diagnosed with IPF according to the diagnostic criteria of the IPF clinical practice guidelines jointly released by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society and the Latin American Thoracic Society in 2022 ; Chest high-resolution computed tomography (HRCT) examination (HRCT examination within 3 months before screening) or lung biopsy (if any) should be confirmed by central reading;
  • The ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) at the screening period is ≥ 0.7;
  • The percentage of FVC as a percentage of the normal predicted value at the screening period is ≥ 45%;
  • The percentage of DLco (hemoglobin [Hb] corrected) as a percentage of the normal predicted value at the screening period is ≥ 30%;
  • Female or male subjects with potential fertility agree and commit to taking effective contraceptive measures from the time of signing the informed consent form until 30 days after the last administration of the investigational drug; at the same time, avoid sperm/egg collection, sperm/egg donation;
  • According to the assessment by the investigator, the subjects are willing and able to comply with the requirements of the protocol and attend the visits.

Exclusion Criteria:

  • The researchers believe that the subjects experienced significant deterioration of IPF within the first three months of the randomization period.
  • Other known causes of interstitial lung disease, such as exposure to the home or occupational environment, connective tissue diseases, drug toxicity, etc.
  • Abnormalities in the lungs or chest that are clinically significant and judged by the researchers to potentially affect the trial results.
  • Within one month before randomization, any active infection requiring systemic treatment (such as oral or intravenous administration) in the form of activity (including bacterial, viral, parasitic or fungal infections).
  • Expected to undergo lung transplantation during the course of the study.
  • Expected survival period less than 6 months.
  • History of malignant tumors within the previous 5 years (excluding localized cancers such as basal cell carcinoma).
  • Moderate to severe liver dysfunction (Child-Pugh classification of grade B or C).
  • Within six months before screening, history of unstable or deteriorating heart disease, including but not limited to the following conditions:
  • Unstable angina pectoris;
  • Myocardial infarction;
  • Congestive heart failure requiring hospitalization or NYHA III/IV grade;
  • Uncontrolled severe arrhythmia.
  • Unable to perform the 6MWT or pulmonary function test, such as if the patient is mentally unstable and unable to cooperate, etc.;
  • Allergic to any component of Ifinonate Hydrochloride Tablets (except the active ingredient, the excipients include microcrystalline cellulose, pre-gelatinized starch, cross-linked povidone, povidone, dibutyl hydroxytoluene, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, talc and titanium dioxide) or pirfenidone tablets;
  • The last administration of the study drug for other clinical trials occurred within 4 weeks before randomization or 5 half-lives (whichever is longer);
  • Pregnant or breastfeeding;
  • Within 3 months before screening, had a smoking history or was unwilling to maintain a smoking-free status during the study;
  • Within 6 months before screening, frequently drank alcohol [average weekly alcohol consumption exceeding 21 units (1 unit = 360 mL of beer, or 150 mL of wine, or 45 mL of 40% alcohol spirits)];
  • Had a history of drug abuse within 6 months before screening;
  • Has a family or personal history of long QT interval syndrome;
  • The investigator believes that the subject has conditions that may compromise their safety or compliance, significantly affect the pharmacokinetics of the drug, or prevent them from completing the study.
  • During the screening period, liver function test values exceeded any of the following standards: total bilirubin > 1.5 times the upper limit of normal (ULN); aspartate aminotransferase or alanine aminotransferase > 2 times ULN;
  • During the screening period, glomerular filtration rate < 45 mL/min/1.73 m2, calculated using the CKD-EPI (based on serum creatinine) formula ;
  • At the time of screening, human immunodeficiency virus antibody or syphilis spirochete antibody test results were positive;
  • At the time of screening, there was an uncontrolled hepatitis B virus infection (positive hepatitis B surface antigen, and hepatitis B DNA ≥ 2x102 IU/mL) or hepatitis C virus infection (positive anti-hepatitis C antibody and hepatitis C RNA);
  • During the screening period, QTcF > 480 ms (using the Fridericia formula, QTcF = QT/RR\^0.33).
  • Those who have previously taken isoniazidine hydrochloride;
  • Within the first 4 weeks before randomization, used any of the following treatments:
  • Any cytotoxic drugs or immunosuppressants, including but not limited to azathioprine, cyclophosphamide, methotrexate, cyclosporine, etc.;
  • Pirfenidone or nintedanib;
  • > 15 mg/d prednisone or equivalent dose of other glucocorticoids;
  • Strong inducers or inhibitors of CYP3A4, CYP2C8 or CYP2C19 (including but not limited to ritonavir, clarithromycin, aletris, carbamazepine, gemfibrozil, fluoxetine, fluvoxamine, etc.);
  • Moderate, strong inhibitors or inducers of CYP1A2 (including but not limited to fluvoxamine, ciprofloxacin, enoxacin, etc.).

Quoted from ClinicalTrials.gov, NCT07082842, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07082842, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07082842